IMA204

About Immatics Biotechnologies

Immatics Biotechnologies is a clinical-stage company dedicated to developing novel T cell receptor (TCR)-based immunotherapies for cancer. Founded in 2000, it has evolved from a platform-focused entity into a product-driven organization with a strategic focus on the PRAME antigen, expressed in over 50 cancer types. The company's integrated technology platforms enable the discovery of novel intracellular targets and the engineering of high-affinity TCRs against them, forming the basis for its pipeline of Adoptive Cell Therapies (ACT) and TCR Bispecifics. Its lead programs are advancing in clinical trials, positioning Immatics as a key player in the next generation of solid tumor oncology.

Therapeutic Areas

Other Undisclosed solid tumors Drugs